目的 探讨芪苈强心联合丹参酮Ⅱ_A磺酸钠治疗心肌梗死的临床疗效。方法 选取2016年6月—2017年6月在焦作煤业（集团）有限责任公司中央医院治疗的心肌梗死患者88例，根据用药差别分为对照组（44例）和治疗组（44例）。对照组静脉滴注丹参酮Ⅱ_A磺酸钠注射液，80 mg加入生理盐水250 mL，1次/d；治疗组在对照组基础上口服芪苈强心胶囊，4粒/次，3次/d。两组均经过4周治疗。观察两组患者临床疗效，比较治疗前后两组患者心功能指标、6 min步行距离（6 WMT）和血清学指标。结果 治疗后，对照组和治疗组临床总有效率分别为79.55%、95.45%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组左心室舒张末期容积（LVEDV）、左心室收缩末期容积（LVESV）和左室舒张末期内经（LVEDD）均明显降低，左心室射血分数（LVEF）和6 WMT明显增加，同组比较差异具有统计学意义（P<0.05）；且治疗组心功能指标和6 WMT改善水平显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清组织型纤溶酶原激活物抑制物1（PAI-1）、心肌肌钙蛋白I（cTnI）、N末端B型钠尿肽原（NT-proBNP）、心型脂肪酸结合蛋白（H-FABP）、可溶性CD40配体（sCD40L）水平均显著降低（P<0.05）；且治疗组血清学指标水平显著低于对照组（P<0.05）。结论 芪苈强心联合丹参酮Ⅱ_A磺酸钠治疗心肌梗死可有效改善患者心功能，改善血清细胞因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Qili Qiangxin Capsules combined with sulfotanshinone sodium in treatment of myocardial infarction. Methods Patients (88 cases) with myocardial infarction in Jiaozuo Coal Industry Group Central Hospital from June 2016 to June 2017 were divided into control (44 cases) and treatment (44 cases) groups based on different treatments. Patients in the control group were iv administered with Sulfotanshinone Sodium Injection, 80 mg added into normal saline 150 mL, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function, 6 WMT and serum cytokine levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 79.55% and 95.45%, respectively, and there were differences between two groups (P < 0.05). After treatment, the LVEDV, LVESV and LVEDD in two groups were significantly decreased, but LVEF and 6 WMT were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the cardiac function and 6 WMT in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the PAI-1, cTnI, NT-proBNP, H-FABP and sCD40L levels in two groups were obviously decreased (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qili Qiangxin Capsules combined with sulfotanshinone sodium in treatment of myocardial infarction can effectively improve cardiac function and serum cytokines level, which has a certain clinical application value.